The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012

on behalf of the SHIVERS investigation team

Research output: Contribution to journalArticleResearchpeer-review

25 Citations (Scopus)

Abstract

Background: Few studies report the effectiveness of trivalent inactivated influenza vaccine (TIV) in preventing hospitalisation for influenza-confirmed respiratory infections. Using a prospective surveillance platform, this study reports the first such estimate from a well-defined ethnically diverse population in New Zealand (NZ). Methods: A case test-negative design was used to estimate propensity adjusted vaccine effectiveness. Patients with a severe acute respiratory infection (SARI), defined as a patient of any age requiring hospitalisation with a history of a fever or a measured temperature ≥38. °C and cough and onset within the past 7 days, admitted to public hospitals in South and Central Auckland were eligible for inclusion in the study. Cases were SARI patients who tested positive for influenza, while non-cases (controls) were SARI patients who tested negative. Results were adjusted for the propensity to be vaccinated and the timing of the influenza season. Results: The propensity and season adjusted vaccine effectiveness (VE) was estimated as 39% (95% CI 16;56). The VE point estimate against influenza A (H1N1) was lower than for influenza B or influenza A (H3N2) but confidence intervals were wide and overlapping. Estimated VE was 59% (95% CI 26;77) in patients aged 45-64 years but only 8% (-78;53) in those aged 65 years and above. Conclusion: Prospective surveillance for SARI has been successfully established in NZ. This study for the first year, the 2012 influenza season, has shown low to moderate protection by TIV against influenza positive hospitalisation.

Original languageEnglish
Pages (from-to)3687-3693
Number of pages7
JournalVaccine
Volume32
Issue number29
DOIs
Publication statusPublished - 17 Jun 2014

Keywords

  • Immunisation
  • Influenza vaccine
  • Vaccination
  • Vaccine effectiveness

Cite this

@article{a2e4978553d748a4940de7752457f6c3,
title = "The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012",
abstract = "Background: Few studies report the effectiveness of trivalent inactivated influenza vaccine (TIV) in preventing hospitalisation for influenza-confirmed respiratory infections. Using a prospective surveillance platform, this study reports the first such estimate from a well-defined ethnically diverse population in New Zealand (NZ). Methods: A case test-negative design was used to estimate propensity adjusted vaccine effectiveness. Patients with a severe acute respiratory infection (SARI), defined as a patient of any age requiring hospitalisation with a history of a fever or a measured temperature ≥38. °C and cough and onset within the past 7 days, admitted to public hospitals in South and Central Auckland were eligible for inclusion in the study. Cases were SARI patients who tested positive for influenza, while non-cases (controls) were SARI patients who tested negative. Results were adjusted for the propensity to be vaccinated and the timing of the influenza season. Results: The propensity and season adjusted vaccine effectiveness (VE) was estimated as 39{\%} (95{\%} CI 16;56). The VE point estimate against influenza A (H1N1) was lower than for influenza B or influenza A (H3N2) but confidence intervals were wide and overlapping. Estimated VE was 59{\%} (95{\%} CI 26;77) in patients aged 45-64 years but only 8{\%} (-78;53) in those aged 65 years and above. Conclusion: Prospective surveillance for SARI has been successfully established in NZ. This study for the first year, the 2012 influenza season, has shown low to moderate protection by TIV against influenza positive hospitalisation.",
keywords = "Immunisation, Influenza vaccine, Vaccination, Vaccine effectiveness",
author = "Nikki Turner and Nevil Pierse and Ange Bissielo and Huang, {Q. Sue} and Baker, {Michael G.} and Widdowson, {Marc Alain} and Heath Kelly and {on behalf of the SHIVERS investigation team} and Colin McArthur",
year = "2014",
month = "6",
day = "17",
doi = "10.1016/j.vaccine.2014.04.013",
language = "English",
volume = "32",
pages = "3687--3693",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "29",

}

The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012. / on behalf of the SHIVERS investigation team.

In: Vaccine, Vol. 32, No. 29, 17.06.2014, p. 3687-3693.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012

AU - Turner, Nikki

AU - Pierse, Nevil

AU - Bissielo, Ange

AU - Huang, Q. Sue

AU - Baker, Michael G.

AU - Widdowson, Marc Alain

AU - Kelly, Heath

AU - on behalf of the SHIVERS investigation team

AU - McArthur, Colin

PY - 2014/6/17

Y1 - 2014/6/17

N2 - Background: Few studies report the effectiveness of trivalent inactivated influenza vaccine (TIV) in preventing hospitalisation for influenza-confirmed respiratory infections. Using a prospective surveillance platform, this study reports the first such estimate from a well-defined ethnically diverse population in New Zealand (NZ). Methods: A case test-negative design was used to estimate propensity adjusted vaccine effectiveness. Patients with a severe acute respiratory infection (SARI), defined as a patient of any age requiring hospitalisation with a history of a fever or a measured temperature ≥38. °C and cough and onset within the past 7 days, admitted to public hospitals in South and Central Auckland were eligible for inclusion in the study. Cases were SARI patients who tested positive for influenza, while non-cases (controls) were SARI patients who tested negative. Results were adjusted for the propensity to be vaccinated and the timing of the influenza season. Results: The propensity and season adjusted vaccine effectiveness (VE) was estimated as 39% (95% CI 16;56). The VE point estimate against influenza A (H1N1) was lower than for influenza B or influenza A (H3N2) but confidence intervals were wide and overlapping. Estimated VE was 59% (95% CI 26;77) in patients aged 45-64 years but only 8% (-78;53) in those aged 65 years and above. Conclusion: Prospective surveillance for SARI has been successfully established in NZ. This study for the first year, the 2012 influenza season, has shown low to moderate protection by TIV against influenza positive hospitalisation.

AB - Background: Few studies report the effectiveness of trivalent inactivated influenza vaccine (TIV) in preventing hospitalisation for influenza-confirmed respiratory infections. Using a prospective surveillance platform, this study reports the first such estimate from a well-defined ethnically diverse population in New Zealand (NZ). Methods: A case test-negative design was used to estimate propensity adjusted vaccine effectiveness. Patients with a severe acute respiratory infection (SARI), defined as a patient of any age requiring hospitalisation with a history of a fever or a measured temperature ≥38. °C and cough and onset within the past 7 days, admitted to public hospitals in South and Central Auckland were eligible for inclusion in the study. Cases were SARI patients who tested positive for influenza, while non-cases (controls) were SARI patients who tested negative. Results were adjusted for the propensity to be vaccinated and the timing of the influenza season. Results: The propensity and season adjusted vaccine effectiveness (VE) was estimated as 39% (95% CI 16;56). The VE point estimate against influenza A (H1N1) was lower than for influenza B or influenza A (H3N2) but confidence intervals were wide and overlapping. Estimated VE was 59% (95% CI 26;77) in patients aged 45-64 years but only 8% (-78;53) in those aged 65 years and above. Conclusion: Prospective surveillance for SARI has been successfully established in NZ. This study for the first year, the 2012 influenza season, has shown low to moderate protection by TIV against influenza positive hospitalisation.

KW - Immunisation

KW - Influenza vaccine

KW - Vaccination

KW - Vaccine effectiveness

UR - http://www.scopus.com/inward/record.url?scp=84901643481&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.04.013

DO - 10.1016/j.vaccine.2014.04.013

M3 - Article

VL - 32

SP - 3687

EP - 3693

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 29

ER -